

UNIQUE N.V.

CASE OVERVIEW

Status: Investigating
Company Name: uniQure N.V.
Ticker: QURE
Related Attorneys: Thomas W. Elrod
Related Practices: Securities

On September 29, 2026, uniQure released 48-month data for ongoing Phase I/II studies of AMT-130, the Company's lead pipeline candidate to treat Huntington's disease. The 48-month data revealed a smaller treatment benefit than the one the Company reported at 36 months. Specifically, AMT-130 showed a "44% slowing of disease progression" at 48 months under the composite Uniform Huntington's Disease Rating Scale, compared to a 75% disease slowing at 36 months. In June, uniQure had announced that the Company intended to submit an application to the FDA to bring AMT-130 to the market and did so on September 2, 2026, submitting a Biologics License Application to the FDA based upon its 36-month data analysis. On the disclosure of the Company's 48-month AMT-130 results, the price of uniQure shares declined by \$14.60 per share, or approximately 37.3%, from \$39.11 per share on September 28, 2026 to close at \$24.51 on September 29, 2026.